<110>    GREEN CROSS CORPORATION
         MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH

<120>    ANTIBODY AGAINST MSLN AND PHARMACEUTICAL COMPOSITION FOR TREATING
         CANCER COMPRISING THE SAME

<130>    PCB810113GCC

<160>    18

<170>    KoPatentIn 3.0

<210>    1
<211>    108
<212>    PRT
<213>    Artificial Sequence

<220>
<223>    VL-1 clone of humanized MI323


<400>    1
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
  1               5                  10                  15 

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Ser Thr Ala
             20                  25                  30 

Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
         35                  40                  45 

Tyr Ser Ala Ser Tyr Arg Tyr Pro Gly Val Pro Ser Arg Phe Ser Gly
     50                  55                  60 

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65                  70                  75                  80 

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Ser Thr Pro Trp
                 85                  90                  95 

Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg
            100                 105            


<210>    2
<211>    108
<212>    PRT
<213>    Artificial Sequence

<220>
<223>    VL domain of mouse MI323


<400>    2
Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly
  1               5                  10                  15 

Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Thr Ala
             20                  25                  30 

Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
         35                  40                  45 

Tyr Ser Ala Ser Tyr Arg Tyr Pro Gly Val Pro Asp Arg Phe Thr Gly
     50                  55                  60 

Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Val Gln Ala
 65                  70                  75                  80 

Glu Asp Leu Ala Leu Tyr Tyr Cys Gln Gln His Tyr Ser Thr Pro Trp
                 85                  90                  95 

Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg
            100                 105            


<210>    3
<211>    119
<212>    PRT
<213>    Artificial Sequence

<220>
<223>    VH-1 clone of humanized MI323


<400>    3
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
  1               5                  10                  15 

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr
             20                  25                  30 

Phe Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met
         35                  40                  45 

Gly Trp Ile Phe Pro Gly Asn Gly Asn Thr Lys Tyr Ser Gln Lys Phe
     50                  55                  60 

Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr
 65                  70                  75                  80 

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                 85                  90                  95 

Ala Arg Ser Gly Gly Tyr Gln Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly
            100                 105                 110 

Thr Leu Val Thr Val Ser Ser
        115                


<210>    4
<211>    119
<212>    PRT
<213>    Artificial Sequence

<220>
<223>    VH-2 clone of humanized MI323


<400>    4
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
  1               5                  10                  15 

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr
             20                  25                  30 

Phe Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
         35                  40                  45 

Gly Gly Ile Phe Pro Gly Ser Gly Asn Ala Asn Tyr Ala Gln Lys Phe
     50                  55                  60 

Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
 65                  70                  75                  80 

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                 85                  90                  95 

Ala Arg Ser Gly Gly Tyr Gln Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly
            100                 105                 110 

Thr Leu Val Thr Val Ser Ser
        115                


<210>    5
<211>    119
<212>    PRT
<213>    Artificial Sequence

<220>
<223>    VH-3 clone of humanized MI323


<400>    5
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Thr
  1               5                  10                  15 

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr
             20                  25                  30 

Phe Ile Gln Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
         35                  40                  45 

Gly Trp Ile Phe Pro Gly Ser Gly Asn Thr Lys Tyr Ser Gln Lys Phe
     50                  55                  60 

Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr
 65                  70                  75                  80 

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                 85                  90                  95 

Ala Arg Ser Gly Gly Tyr Gln Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly
            100                 105                 110 

Thr Leu Val Thr Val Ser Ser
        115                


<210>    6
<211>    119
<212>    PRT
<213>    Artificial Sequence

<220>
<223>    VH domain of mouse MI323


<400>    6
Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Thr
  1               5                  10                  15 

Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr
             20                  25                  30 

Phe Ile Gln Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
         35                  40                  45 

Gly Trp Ile Phe Pro Gly Ser Gly Asn Thr Lys Tyr Asn Glu Met Phe
     50                  55                  60 

Lys Gly Lys Ala Thr Leu Ala Ala Asp Thr Ser Ser Ser Thr Ala Tyr
 65                  70                  75                  80 

Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys
                 85                  90                  95 

Ala Arg Ser Gly Gly Tyr Gln Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly
            100                 105                 110 

Thr Ser Val Thr Val Ser Ser
        115                


<210>    7
<211>    106
<212>    PRT
<213>    Artificial Sequence

<220>
<223>    kappa CL domain


<400>    7
Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
  1               5                  10                  15 

Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
             20                  25                  30 

Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
         35                  40                  45 

Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
     50                  55                  60 

Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
 65                  70                  75                  80 

His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
                 85                  90                  95 

Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
            100                 105    


<210>    8
<211>    330
<212>    PRT
<213>    Artificial Sequence

<220>
<223>    IgG1 CH domain


<400>    8
Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
  1               5                  10                  15 

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
             20                  25                  30 

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
         35                  40                  45 

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
     50                  55                  60 

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
 65                  70                  75                  80 

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
                 85                  90                  95 

Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
            100                 105                 110 

Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
        115                 120                 125 

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
    130                 135                 140 

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
145                 150                 155                 160 

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
                165                 170                 175 

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
            180                 185                 190 

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
        195                 200                 205 

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
    210                 215                 220 

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu
225                 230                 235                 240 

Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
                245                 250                 255 

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
            260                 265                 270 

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
        275                 280                 285 

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
    290                 295                 300 

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
305                 310                 315                 320 

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
                325                 330


<210>    9
<211>    11
<212>    PRT
<213>    Artificial Sequence

<220>
<223>    Amino acid seqeunce for anti-MSLN antibody of CDR1 (VL)


<400>    9
Arg Ala Ser Gln Asp Val Ser Thr Ala Val Ala
  1               5                  10    


<210>    10
<211>    7
<212>    PRT
<213>    Artificial Sequence

<220>
<223>    Amino acid seqeunce for anti-MSLN antibody of CDR2 (VL)


<400>    10
Ser Ala Ser Tyr Arg Tyr Pro
  1               5        


<210>    11
<211>    9
<212>    PRT
<213>    Artificial Sequence

<220>
<223>    Amino acid seqeunce for anti-MSLN antibody of CDR3 (VL)


<400>    11
Gln Gln His Tyr Ser Thr Pro Trp Thr
  1               5                


<210>    12
<211>    10
<212>    PRT
<213>    Artificial Sequence

<220>
<223>    Amino acid seqeunce for anti-MSLN antibody of CDR1 (VH)


<400>    12
Gly Tyr Ser Phe Thr Ser Tyr Phe Met His
  1               5                  10


<210>    13
<211>    10
<212>    PRT
<213>    Artificial Sequence

<220>
<223>    Amino acid seqeunce for anti-MSLN antibody of CDR1 (VH)


<400>    13
Gly Tyr Ser Phe Thr Ser Tyr Phe Ile Ser
  1               5                  10


<210>    14
<211>    10
<212>    PRT
<213>    Artificial Sequence

<220>
<223>    Amino acid seqeunce for anti-MSLN antibody of CDR1 (VH)


<400>    14
Gly Tyr Ser Phe Thr Ser Tyr Phe Ile Gln
  1               5                  10


<210>    15
<211>    17
<212>    PRT
<213>    Artificial Sequence

<220>
<223>    Amino acid seqeunce for anti-MSLN antibody of CDR2 (VH)


<400>    15
Trp Ile Phe Pro Gly Asn Gly Asn Thr Lys Tyr Ser Gln Lys Phe Gln
  1               5                  10                  15 

Gly
   


<210>    16
<211>    17
<212>    PRT
<213>    Artificial Sequence

<220>
<223>    Amino acid seqeunce for anti-MSLN antibody of CDR2 (VH)


<400>    16
Gly Ile Phe Pro Gly Ser Gly Asn Ala Asn Tyr Ala Gln Lys Phe Gln
  1               5                  10                  15 

Gly
   


<210>    17
<211>    17
<212>    PRT
<213>    Artificial Sequence

<220>
<223>    Amino acid seqeunce for anti-MSLN antibody of CDR2 (VH)


<400>    17
Trp Ile Phe Pro Gly Ser Gly Asn Thr Lys Tyr Ser Gln Lys Phe Gln
  1               5                  10                  15 

Gly
   


<210>    18
<211>    10
<212>    PRT
<213>    Artificial Sequence

<220>
<223>    Amino acid seqeunce for anti-MSLN antibody of CDR3 (VH)


<400>    18
Ser Gly Gly Tyr Gln Tyr Tyr Phe Asp Tyr
  1               5                  10
